Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=6&sort=funder_divisions
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=funder_divisions", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1442&sort=funder_divisions", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=7&sort=funder_divisions", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=5&sort=funder_divisions" }, "data": [ { "type": "Grant", "id": "8471", "attributes": { "award_id": "2U60OH010902-06", "title": "Montana Occupational Health and Safety Surveillance Program", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 22791, "first_name": "Linda", "last_name": "West", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-07-01", "end_date": "2026-06-30", "award_amount": 155000, "principal_investigator": { "id": 24234, "first_name": "Emily", "last_name": "Healy", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1714, "ror": "", "name": "MONTANA DEPARTMENT OF LABOR AND INDUSTRY", "address": "", "city": "", "state": "MT", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1714, "ror": "", "name": "MONTANA DEPARTMENT OF LABOR AND INDUSTRY", "address": "", "city": "", "state": "MT", "zip": "", "country": "United States", "approved": true }, "abstract": "Montana Department of Labor and Industry Montana Occupational Health & Safety Surveillance (MOHSS) PAR-20-312 Project Summary The Montana Occupational Health and Safety Surveillance (MOHSS) program works to accomplish three main goals in order bridge the gap between occupational health surveillance and prevention and safety activities. MOHSS accomplishes this through three primary activities that all together can provide valuable information and lead to occupational health improvement across the state. Expected outputs of the program include reports, publications, presentations, award, policies, and legislation that will lead to the outcomes of reduced workplace injuries, illness, and fatalities. The program collects, reports, and analyzes the Occupational Health Indicators as a baseline for occupational health surveillance. The indicators collected on an annual basis allow for an analysis of trends in occupational health. They are used to monitor Montana’s occupational safety and health landscape, reveal areas in need of more in-depth surveillance, and guide prevention efforts. MOHSS also uses interagency collaborations to improve the quantity and quality of occupational health data collected and used for surveillance. MOHSS works to improve access to and quality of existing systems as well as explore new data sources. In order to accomplish this, MOHSS collaborates with other agencies and bureaus within Montana to take advantage of the large variety of surveillance systems already in place. These include the Montana Department of Public Health and Human Services, Montana Department of Transportation, Montana Department of Environmental Quality, Montana university system, and other outside organizations. The collaborations allow for research on emerging issues such as COVID-19 and new occupational safety and health topics like Total Worker Health. Finally, MOHSS creates and maintains active communication with stakeholders in occupational safety and health to provide avenues through which information from MOHSS research can reach agencies who are able to act on the findings. Findings from MOHSS guide interventions and preventative policy targeting occupational health and safety hazards most efficiently. These relationships also provide external guidance to MOHSS and provide council on aspects of occupational health of particular importance or concern.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "8720", "attributes": { "award_id": "6U01IP001160-01M003", "title": "Collaborative Research on Influenza, Coronavirus Disease 2019 (COVID-19), and Other Respiratory Pathogens in South Africa", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2021-09-01", "end_date": "2024-08-31", "award_amount": 175000, "principal_investigator": { "id": 24504, "first_name": "Cheryl", "last_name": "Cohen", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1742, "ror": "https://ror.org/00znvbk37", "name": "National Health Laboratory Service", "address": "", "city": "", "state": "", "zip": "", "country": "SOUTH AFRICA", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1742, "ror": "https://ror.org/00znvbk37", "name": "National Health Laboratory Service", "address": "", "city": "", "state": "", "zip": "", "country": "SOUTH AFRICA", "approved": true }, "abstract": null, "keywords": [], "approved": true } }, { "type": "Grant", "id": "8205", "attributes": { "award_id": "1R01HS027595-01A1", "title": "The effect of voluntary bundled payments on vulnerable populations", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 24040, "first_name": "Fred", "last_name": "Hellinger", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-04-01", "end_date": "2025-03-31", "award_amount": 396115, "principal_investigator": { "id": 24041, "first_name": "Joshua M", "last_name": "Liao", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 232, "ror": "https://ror.org/00b30xv10", "name": "University of Pennsylvania", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 24042, "first_name": "Amol S", "last_name": "Navathe", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 232, "ror": "https://ror.org/00b30xv10", "name": "University of Pennsylvania", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "To inform payment policy that promotes parity, this study examines how voluntary bundled payments impact access and outcomes for racial minorities, ethnic minorities, and individuals with low socioeconomic status (SES), vulnerable groups that have long faced disparities in health care access and outcomes. This application aligns with the Special Emphasis Notice Health Services Research Priorities for Achieving a High Value Healthcare System (NOT-HS-19-011) Priority Area #3: Payment for outcomes. Voluntary bundled payments could exacerbate existing disparities if participating providers perceive that vulnerable patients’ outcomes are difficult to manage and avoid participating in the payment model (i.e., provider selection) or participate but avoid caring for vulnerable groups (i.e., patient selection). It is also vital to understand how impacts on disparities vary based on providers’ mission and experience caring for vulnerable groups (e.g., safety-net vs. non-safety-net providers). Such insights are particularly critical for lower extremity joint replacement (LEJR), congestive heart failure (CHF), and sepsis – the most prevalent procedures and conditions that are both marked by significant, existing disparities and targeted by voluntary bundled payment programs. The insights generated by this proposal are also critical given the impact of COVID-19 on both payment reform and health care disparities. We hypothesize that providers participating in voluntary bundled payment programs will be less likely than non-participants to be located in markets with a high proportion of vulnerable individuals; that disparities in access and outcomes will widen for vulnerable patients, as compared to other patients, after providers start participating in voluntary bundled payments compared to providers that do not participate; that these effects will vary by racial minority versus ethnic minority status, and interactions between racial and ethnic minority status and low SES; and that disparities will widen less at safety-net versus non-safety-net providers.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "8707", "attributes": { "award_id": "6R03OH012215-01M002", "title": "COVID-19 Exposure, Response, Physical and Mental Health Sequelae among Nurses in New York State", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 24486, "first_name": "Maria", "last_name": "Lioce", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-09-01", "end_date": "2023-08-30", "award_amount": 80724, "principal_investigator": { "id": 24491, "first_name": "Marlene", "last_name": "Camacho", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 815, "ror": "https://ror.org/0041qmd21", "name": "SUNY Downstate Medical Center", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 815, "ror": "https://ror.org/0041qmd21", "name": "SUNY Downstate Medical Center", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": null, "keywords": [], "approved": true } }, { "type": "Grant", "id": "9472", "attributes": { "award_id": "6U48DP006382-02M002", "title": "Connecting Behavioral Science to COVID-19 Vaccine Demand (CBS-CVD) Network Supplement for PRC - Increasing Effective Mental Health Care for LGBT Clients", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2019-09-30", "end_date": "2024-09-29", "award_amount": 500000, "principal_investigator": { "id": 25187, "first_name": "BRADLEY O", "last_name": "BOEKELOO", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1021, "ror": "", "name": "UNIV OF MARYLAND, COLLEGE PARK", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1021, "ror": "", "name": "UNIV OF MARYLAND, COLLEGE PARK", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": null, "keywords": [], "approved": true } }, { "type": "Grant", "id": "11011", "attributes": { "award_id": "5U01IP001150-02", "title": "Surveillance for Vaccine Preventable Disease in Children", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2021-09-01", "end_date": "2023-08-31", "award_amount": 1936000, "principal_investigator": { "id": 24475, "first_name": "Julie Anne", "last_name": "Boom", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 566, "ror": "https://ror.org/02pttbw34", "name": "Baylor College of Medicine", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 24476, "first_name": "Leila C", "last_name": "Sahni", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 566, "ror": "https://ror.org/02pttbw34", "name": "Baylor College of Medicine", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true }, "abstract": "Component A: Project Summary Texas Children’s Hospital (TCH) aims to continue inpatient and emergency department surveillance as part of the larger national New Vaccine Surveillance Network (NVSN) to assess the burden of pediatric respiratory and gastrointestinal illnesses and acute flaccid myelitis in hospitalized children and children seeking care in the emergency department. Specifically, we will operate year-round surveillance to assess the burden of multiple viral and bacterial respiratory pathogens, including but not limited to SARS-CoV-2, influenza, respiratory syncytial virus, human metapneumovirus, parainfluenza virus, coronavirus, rhinovirus, and emerging respiratory pathogens, such as enterovirus D68. A concurrent group of healthy, asymptomatic children presenting to Texas Children’s Pediatric practices for well child care will be enrolled as a control group. Nose and/or throat swabs will be collected from symptomatic and healthy control children and tested for a wide array of respiratory pathogens using molecular methods in the laboratory of Dr. Pedro Piedra, a national expert in pediatric respiratory disease. In addition, we will assess the burden of gastrointestinal pathogens such as rotavirus and norovirus. Stool specimens from symptomatic patients and healthy control children will undergo molecular testing in the labs of Dr. Robert Atmar and Dr. Sasirekha Ramani at Baylor College of Medicine. Complete vaccination histories will be obtained for all children based on our well-established process for gathering vaccination histories. We will calculate baseline and population-based rates of respiratory and enteric pathogens among hospitalized and ED patients. Using a test negative study design, we will calculate vaccine effectiveness for vaccine-preventable diseases such as influenza, rotavirus and SARS-CoV-2, comparing symptomatic patients who test positive for a pathogen of interest to symptomatic patients and asymptomatic, healthy controls who test negative for the specific pathogen. Importantly, TCH is an exemplary surveillance site due the large number of admissions each year (>36,000), racial and ethnic diversity of the Houston area, and the similarity of the TCH population to that of the community. Given the large number of admissions per year and depth of local neurologic expertise, TCH represents the ideal site for conducting year- round surveillance for children with acute flaccid myelitis (AFM) and comparing rates of AFM with rates of circulating respiratory and gastrointestinal pathogens.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "8217", "attributes": { "award_id": "1IK6BX005692-01", "title": "BLRD Research Career Scientist Award Application", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2021-04-01", "end_date": "2026-03-31", "award_amount": null, "principal_investigator": { "id": 24051, "first_name": "Robert", "last_name": "Raffai", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1522, "ror": "", "name": "VETERANS AFFAIRS MED CTR SAN FRANCISCO", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1522, "ror": "", "name": "VETERANS AFFAIRS MED CTR SAN FRANCISCO", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "The overall goal of this Research Career Scientist award is to foster the nominee’s ongoing research program that is focused on the study of extracellular vesicles (EVs) and their extracellular RNA (exRNA) cargo as biomarkers and effectors of human health and disease including among Veterans. Through participation in a national NIH-funded consortium research program, the nominee is working to develop novel methods to study EVs and other carriers of exRNA for biomarker development projects. The nominee also recently reported the first evidence of intercellular signaling between macrophage EVs and hematopoietic progenitor cells to control the process of systemic and vascular inflammation and atherosclerosis cardiovascular disease. Ongoing funding from a VA Merit grant is supporting the nominee’s goal of exploring the role of circulating EVs isolated from Veterans treated for advanced vascular disease as biomarkers and contributors to disease progression including via microRNA cargo. Experiments in the lab will also test if EVs produced from anti- inflammatory macrophages can serve to control inflammation and atherosclerosis in diabetic rodent models. Furthermore, funding from a VA Invention-based Supplement Award will support pre-clinical studies testing such anti-inflammatory EVs as therapeutics to control cardiac inflammation and heart failure in a rodent model system developed and patented for the VA by the nominee. Findings from these studies could provide much needed new therapeutics in the form of EV-biologics to treat inflammatory diseases including in the cardiovascular system that is a major healthcare need among the Veteran patient population. The nominee’s internationally recognized program on EV biology has led to new collaborative research projects with VA clinician investigators at the local and offsite stations. This includes a collaborative project to test EVs produced by cultured stem cells as therapeutic mediators of skeletal muscle regeneration. Such studies have been proposed in a VA Merit grant proposal with the nominee serving as co-Investigator, which is being revised for a resubmission. The nominee is also engaged in collaborative studies with VA clinician investigators to develop biomarkers of adverse outcomes of surgical procedures used to treat advanced vascular disease among Veterans. Finally, projects proposed by the nominee through grants pending at the Department of VA and the NIH make use of EV technology and expertise developed by the nominee to address the COVID19 disease crisis. This includes by making use of new methods of EV detection in biofluids to develop biomarkers for clinical outcomes of COVID19 disease. It also includes developing new forms of engineered EVs designed to serve in improving host immune response against SARS-CoV-2 viral infection as well as to control lung inflammation. Together, the award will serve to sustain the nominee’s momentum to developing a first-in-class research program centered on the study of EVs as biomarkers and biologics to control tissue inflammation and remodeling including in the cardiovascular system. It will also allow to expand the nominees network of collaborators with clinician and basic scientists within the VA intramural research program, as well as at local, national and international sites to widely disseminate and implement expertise in the study of EVs as biologics to improve the diagnosis and treatment of diseases in priority areas to the VA. Furthermore, it will allow the nominee to increase professional service to local and national committees including within the VA and maintain teaching and mentoring to next generation research investigators and clinician scientists within the VA research program.", "keywords": [ "2019-nCoV", "Achievement", "Address", "Alzheimer&apos", "s disease model", "Anti-Inflammatory Agents", "Apolipoprotein E", "Applications Grants", "Area", "Atherosclerosis", "Award", "Biological", "Biological Markers", "Biological Models", "Biology", "Blood Circulation", "Blood Vessels", "COVID-19", "Cardiovascular Diseases", "Cardiovascular system", "Cells", "Clinical", "Collaborations", "Communication", "Coronary Arteriosclerosis", "Country", "Detection", "Diagnosis", "Diet", "Disclosure", "Disease", "Disease Progression", "Educational process of instructing", "Engineering", "Faculty", "Fostering", "Foundations", "Funding", "Goals", "Grant", "Growth", "Health", "Healthcare", "Healthcare Systems", "Heart failure", "Hematopoietic stem cells", "Host Defense", "Human", "Immune", "Immune response", "Immunologic Tests", "Inflammation", "Inflammatory", "Institution", "Intellectual Property", "International", "Intramural Research Program", "Journals", "Laboratories", "Lead", "Legal patent", "Los Angeles", "Lung Inflammation", "Mediator of activation protein", "Medical Research", "Medical Students", "Medical center", "Mentors", "Methods", "MicroRNAs", "Mission", "Molecular", "Myocarditis", "Operative Surgical Procedures", "Outcome", "Pathogenesis", "Peripheral", "Postdoctoral Fellow", "Principal Investigator", "Process", "Professional Organizations", "Property Rights", "Proteins", "Publications", "Publishing", "RNA", "Reporting", "Research", "Research Personnel", "Research Project Grants", "Resources", "Rodent Model", "Role", "Scientist", "Services", "Signal Transduction", "Site", "Skeletal Muscle", "Technology", "Testing", "Therapeutic", "Tissues", "Translations", "United States National Institutes of Health", "Vascular Diseases", "Ventricular Remodeling", "Veterans", "Virus", "Virus Diseases", "adverse outcome", "base", "biomarker development", "career", "design", "diabetic", "experimental study", "extracellular", "extracellular vesicles", "fighting", "graduate student", "health care delivery", "improved", "insight", "invention", "macrophage", "muscle regeneration", "neuroinflammation", "next generation", "novel", "novel therapeutics", "patient population", "preclinical study", "programs", "recruit", "research and development", "stem cells", "systemic inflammatory response", "therapeutic evaluation", "therapy development", "tissue repair", "vascular inflammation" ], "approved": true } }, { "type": "Grant", "id": "4102", "attributes": { "award_id": "NNX16AK48G", "title": "ASTEROID 2008 TC3 WAS TRACKED AND STUDIED IN SPACE FOR ~19 HOURS BEFORE IT IMPACTED EARTH'S ATMOSPHERE AND SHATTERED OVER NORTHERN SUDAN ON OCTOBER 7, 2008.WE WILL CONDUCT PETROLOGIC STUDIES, OXYGEN ISOTOPE ANALYSES, AR-AR DATING, AND SPECTROSCOPIC MEASUR", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2016-05-23", "end_date": "2017-05-22", "award_amount": 0, "principal_investigator": { "id": 13774, "first_name": "CYRENA", "last_name": "GOODRICH", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "ASTEROID 2008 TC3 WAS TRACKED AND STUDIED IN SPACE FOR ~19 HOURS BEFORE IT IMPACTED EARTH'S ATMOSPHERE AND SHATTERED OVER NORTHERN SUDAN ON OCTOBER 7, 2008.WE WILL CONDUCT PETROLOGIC STUDIES, OXYGEN ISOTOPE ANALYSES, AR-AR DATING, AND SPECTROSCOPIC MEASUR", "keywords": [], "approved": true } }, { "type": "Grant", "id": "9493", "attributes": { "award_id": "6U48DP006381-03M001", "title": "UMass Worcester Prevention Research Center - COVID 19 Supplement", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2019-09-30", "end_date": "2024-09-29", "award_amount": 310000, "principal_investigator": { "id": 25202, "first_name": "Stephenie C.", "last_name": "Lemon", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 790, "ror": "", "name": "UNIV OF MASSACHUSETTS MED SCH WORCESTER", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 25203, "first_name": "MILAGROS C", "last_name": "ROSAL", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 790, "ror": "", "name": "UNIV OF MASSACHUSETTS MED SCH WORCESTER", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": null, "keywords": [], "approved": true } }, { "type": "Grant", "id": "7944", "attributes": { "award_id": "1I01HX003364-01A1", "title": "Dissemination and Implementation of a Videoconference Antimicrobial Stewardship Team (VAST)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2022-05-01", "end_date": "2026-04-30", "award_amount": null, "principal_investigator": { "id": 23816, "first_name": "CHARLESNIKA T", "last_name": "EVANS", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1483, "ror": "https://ror.org/01vrybr67", "name": "Louis Stokes Cleveland VA Medical Center", "address": "", "city": "", "state": "OH", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 23817, "first_name": "Robin", "last_name": "Jump", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1483, "ror": "https://ror.org/01vrybr67", "name": "Louis Stokes Cleveland VA Medical Center", "address": "", "city": "", "state": "OH", "zip": "", "country": "United States", "approved": true }, "abstract": "Background: Antimicrobial stewardship guidelines call for a multidisciplinary team with an infectious disease (ID) physician and ID-trained clinical pharmacist as core members. Unfortunately, there are insufficient ID- trained specialists to staff on-site antimicrobial stewardship programs throughout VA. Significance: This proposal is highly significant for Veterans and the goals of VA. Veterans experience many of the risk factors associated with development of antimicrobial resistant and healthcare-associated infections. The unprecedented effects of the novel Coronavirus disease 2019 (COVID-19) on the health of our Veterans and on our entire healthcare system makes the demand for ID expertise even more apparent, especially in long-term care. Also, this study directly addresses the VA MISSION ACT to improve access to care, timeliness and quality of care, using telehealth services. Finally, this project is aligned with the priorities of our operation partners: VA Antimicrobial Stewardship Taskforce (ASTF), the VA National Infectious Disease Service (NIDS), VA Pharmacy Benefits Management (PBM) Services, and the Office of Rural Health. Innovation and Impact: The design is innovative because we will systematically test and assess implementation barriers to telehealth for antimicrobial stewardship, a novel approach that has not been implemented in VA facilities, other than in our previous pilot study. Further, the Antibiotic Use Reports (AURs) are an innovative adaptation of peer-comparison, an antibiotic stewardship strategy successful in outpatient settings. This project will provide findings for a scalable model that could be deployed nationally to all applicable VAMCs, continuing the role of VHA as a leader in implementing large-scale interventions focused on prevention and management of ID and stewardship. Specific Aims: Our goal is to implement a multidisciplinary videoconference antimicrobial stewardship team (VAST) in VAMCs using SCAN-ECHO. Our central hypothesis is that feedback reports that quantify facility- level antibiotic use will enhance the efficacy of VASTs to support antimicrobial stewardship. We propose a Type 2 hybrid effectiveness-implementation design, comparing clinical effectiveness in sites that implement the VAST alone (VAST-) to sites that implement the VAST augmented by facility-level Antibiotic Use Reports (VAST+). Aims are: 1) Identify and test effective strategies for implementing the VAST; 2) Determine the influence of the VAST overall and VAST+ on the care of Veterans with suspected infections; 3) Determine the influence of the VAST overall and VAST+ on antibiotic use at each VAMC. Methodology: We will randomize rural VAMCs that do not have ID-trained professionals on staff to implement the VAST alone (VAST-) versus VAST + antibiotic use feedback (VAST+). Aim 1: We will assess modification and adaptations at the intervention sites and by the infectious disease experts. Methods will include process maps and semi-structured interviews to gather qualitative data about what key VAST members perceive as facilitators, barriers and burden to VAST implementation. We will also evaluate costs of implementation. Aim 2: We will evaluate the Veteran population served, clinical activities, and user perceptions of the VAST. We will assess the concordance of clinical care with recommendations from evidence-based clinical practice guidelines. VAST members’ perceptions of the quality and timeliness of care will be evaluated. Aim 3: The primary outcome measure will be overall rates of antibiotic use. Secondary outcomes will be changes in the rates of broad-spectrum antibiotic use, antibiotic starts, and length of antibiotic therapy. Next steps/Implementation: Testing effective implementation of the VAST at additional VAMCs is an important step toward augmenting antimicrobial stewardship in both acute- and long-term care settings. In collaboration with VA clinical operation partners, outcomes from this trial will be used to roll-out an implementation playbook to be used by other VAMCs, as well as non-VA settings.", "keywords": [ "Acute", "Address", "Administrator", "Affect", "Antibiotic Therapy", "Antibiotics", "Antimicrobial Resistance", "Area", "COVID-19", "Caring", "Cellulitis", "Cessation of life", "Clinical", "Clinical Nurse Specialists", "Clinical Pharmacists", "Clinical Practice Guideline", "Clinical effectiveness", "Collaborations", "Communicable Diseases", "Community Healthcare", "Complex", "Consultations", "Data", "Development", "Dissemination and Implementation", "Effectiveness", "Evidence based intervention", "Feedback", "Goals", "Guidelines", "Health", "Health Services Accessibility", "Healthcare", "Healthcare Systems", "Improve Access", "Individual", "Infection", "Infection Control", "Intervention", "Interview", "Length", "Long-Term Care", "Maps", "Measures", "Medical center", "Mentors", "Methodology", "Methods", "Modeling", "Modification", "Outcome", "Outcome Measure", "Outpatients", "Participant", "Patient Care", "Perception", "Pharmacists", "Physicians", "Pilot Projects", "Pneumonia", "Policy Maker", "Prevention", "Process", "Provider", "Quality of Care", "Randomized", "Recommendation", "Reporting", "Resources", "Risk Factors", "Role", "Rural", "Rural Health", "Services", "Site", "Specialist", "Structure", "System", "Testing", "Time", "Training", "United States Department of Veterans Affairs", "Urinary tract infection", "Veterans", "Work", "antimicrobial", "base", "care outcomes", "care providers", "clinical care", "combat", "design", "effectiveness implementation design", "effectiveness implementation study", "evidence base", "evidence based guidelines", "experience", "feasibility testing", "geographically distant", "global health", "healthcare-associated infections", "implementation barriers", "implementation cost", "implementation evaluation", "improved", "innovation", "interest", "medical specialties", "member", "military veteran", "multidisciplinary", "novel coronavirus", "novel strategies", "operation", "pathogen", "patient safety", "patient subsets", "peer", "pharmacy benefit", "prevent", "primary outcome", "programs", "secondary outcome", "telehealth" ], "approved": true } } ], "meta": { "pagination": { "page": 6, "pages": 1442, "count": 14420 } } }